Caltech/UCLA Individualized Theranostic Engineering to Advance Metabolic System (iTEAM)

加州理工学院/加州大学洛杉矶分校个性化治疗诊断工程促进代谢系统 (iTEAM)

• 批准号: 10213026
• 负责人: Dino Di Carlo
• 金额: $ 29.19万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-08 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10213026
• 关键词: Engineering; Metabolic; System; theranostics

ABSTRACT The California Institute of Technology (Caltech) and the University of California at Los Angeles (UCLA) have partnered to integrate advanced imaging and sensing coupled with computing needed to translate technological innovation to address the global cardiometabolic disease. The UCLA/Caltech integrated Theranostic Engineering to Advance Metabolic Medicine (iTEAM) Program represents a new paradigm that will be formalized into a 2-year, structured curriculum with an emphasis on recruiting the under-represented post-doctoral engineers or physical scientists into leadership roles in academia and industry. The convergence of the fundamental strengths of Caltech and clinical strengths of UCLA is conducive to individualize training in 1) advanced sensing or 2) imaging coupled with computing to address 3) cardiometabolic disease. The iTEAM program is partnering with industry leaders (Amgen, Johnson & Johnson, Medtronic, and Edwards Lifesciences) for internship, mentorship, and leadership programs. Both the Caltech Diversity Center and UCLA Faculty Diversity & Development Office have supported workshops on Science Technology Engineering & Mathematics (STEM) for women and underrepresented minorities. To implement this UCLA/Caltech iTEAM program, we have developed a mentoring and self-evaluating structure in the inclusion of 21 primary and co-mentors, 13 consulting mentors, and 10 industry leaders (42% female). Each iTEAM scholar will have co-mentorships: a primary mentor from enabling technologies and a secondary from cardiometabolic medicine and/or industry. In Year 1, iTEAM scholars will: 1) Participate in an initial two- day workshop including mentors, program leaders, clinicians, physician-scientists, and industry leaders to explore projects, expectations, mentorship, and goals; 2) Meet one-to-one with the Program Director(s) to finalize a primary (imaging or sensing) and a co-mentor (cardiometabolic disease or industry); 3) Develop an Individualized Development Plans (IDP) with the Advising & Training Committee to finalize the project; and 4) Strengthen fundamental knowledge in advanced imaging, sensors, or computation and didactic training for ethics in biomedical research and publications. In Year 2, iTEAM scholars will be afforded 1) the opportunity to present work-in-progress and provide feedback in quarterly meetings with a primary mentor and with a co- mentor, 2) an option to participate in a certificate in Pathways in Clinical and Translational Research from the UCLA Clinical Translational Science Institute (CTSI) or Law and Technology for FDA regulatory science (BE188/299); and/or 3) to participate in UCLA CTSI-sponsored professional development in preparation for an academic or industry career. Both Caltech and UCLA Deans have committed matching funds for each iTEAM scholar. UCLA Vice Provost for Graduate Education and has also committed supplemental trainee support to enhance the diversity of trainees. Overall, this program infuses the scientific workforce with the next generation of theranostic bioengineers prepared to solve the worldwide threat of cardiometabolic disease.

摘要 加州理工学院（Caltech）和位于洛杉矶的加州大学（UCLA）已经 合作将先进的成像和传感技术与所需的计算技术相结合， 技术创新，以解决全球心脏代谢疾病。加州大学洛杉矶分校/加州理工学院综合 治疗诊断工程推进代谢医学（iTEAM）计划代表了一种新的范式， 将正式成为一个2年，结构化的课程，重点是招聘代表性不足 博士后工程师或物理科学家进入学术界和工业界的领导角色。的 加州理工学院的基本优势和加州大学洛杉矶分校的临床优势的融合有利于 在1）高级感知或2）成像与计算方面进行个性化培训，以解决3） 心脏代谢疾病iTEAM计划与行业领导者（安进、约翰逊和 约翰逊、美敦力和Edwards Lifesciences）的实习、指导和领导力计划。两者 加州理工学院多元化中心和加州大学洛杉矶分校教师多元化与发展办公室支持举办研讨会， 科学技术工程和数学（STEM）为妇女和代表性不足的少数民族。到 为了实施UCLA/Caltech iTEAM计划，我们开发了一个指导和自我评估结构， 包括21名主要和共同导师、13名咨询导师和10名行业领导者（42%为女性）。 每个iTEAM学者将有共同导师：一个主要的导师从使能技术和第二个 心脏代谢医学和/或工业。在第一年，iTEAM学者将：1）参加最初的两个- 为期一天的研讨会，包括导师，项目负责人，临床医生，医生，科学家和行业领导者， 探索项目、期望、指导和目标; 2）与项目总监一对一会面， 最终确定主要（成像或传感）和共同导师（心脏代谢疾病或行业）; 3）制定 与咨询和培训委员会一起制定个性化发展计划，以最终确定项目;以及4） 加强先进成像、传感器或计算的基础知识， 生物医学研究和出版物中的伦理学。在第二年，iTEAM学者将获得1）机会， 在与主要导师和共同导师的季度会议上展示正在进行的工作并提供反馈， 导师，2）参加临床和转化研究途径证书的选项 加州大学洛杉矶分校临床转化科学研究所（CTSI）或FDA监管科学法律与技术 （BE 188/299）;和/或3）参加加州大学洛杉矶分校CTSI赞助的专业发展，为 学术或工业生涯。加州理工学院和加州大学洛杉矶分校的院长都承诺为每个iTEAM提供配套资金 学者加州大学洛杉矶分校研究生教育副教务长，并承诺补充实习生的支持， 加强学员的多样性。总的来说，这个项目为下一代科学工作者注入了活力。 治疗诊断学生物工程师准备解决心脏代谢疾病的全球威胁。